Early detection plays a vital role in the fight against cancer, as it significantly increases the chances of successful treatment and survival. Unfortunately, traditional cancer testing methods, which often rely on symptom-based diagnoses, lead to nearly 50% of patients being diagnosed at more advanced stages. This often results in the need for aggressive treatments and poorer outcomes. Health Today now offers LucenceINSIGHT™, a cutting-edge screening technology that enables Canadians to detect cancer earlier. This innovative test helps reduce the risk of late-stage diagnosis, giving individuals the opportunity to take control of their health and improve their chances of a positive outcome.
How Does LucenceINSIGHT™ Testing Work?
LucenceINSIGHT™ works by conducting a single blood test to screen for signatures of multiple cancers, including breast, ovarian, cervical, pancreatic, liver, colorectal, stomach, prostate, and bladder cancers, (when applicable). After collecting your sample, The Health Today team ships to a lab for processing. Results are provided in 7-10 days for LucenceINSIGHT™, and 14-21 days for LucenceINSIGHT™ PLUS.
Early Detection Is Key For Optimal Outcomes
Early detection of cancer signatures and prompt diagnosis provides significant benefits to patients, including:
Rapid response with further testing and active surveillance
Reduced need for invasive interventions, leading to decreased cancer progression and faster recovery
Increased rates of cancer remission
Lower costs of treatment, including financial and quality of life costs
Higher survival rates
Yet, despite the availability of early detection technologies, 40% of screenable cancers are still diagnosed at advanced stages, highlighting the need for greater awareness and proactive screening measures.
Introducing LucenceINSIGHT™
Health Today Inc. proudly introduces LucenceINSIGHT™, a groundbreaking multi-cancer early detection (MCED) tool designed to revolutionize cancer care for Canadians. By harnessing a simple blood draw, LucenceINSIGHT™ screens for the signal of up to 50 cancers with unprecedented precision. Thanks to its proprietary amplicon-based technology, the tool boasts an impressive sensitivity of 80.9% and specificity of 99%, identifying critical single nucleotide variations (SNVs), indels, and cancer-associated viruses such as Epstein-Barr virus (EBV) and Human Papillomavirus (HPV) in circulating tumor DNA (ctDNA).
What sets LucenceINSIGHT™ apart is its innovative use of data to generate a localization signal, predicting with 88% accuracy the potential origins of the cancer signal within the body. This feature, known as Predicted Signal Localization, is a game-changer, offering valuable insights that direct further confirmatory diagnostic testing. For Canadians, LucenceINSIGHT™ offers a beacon of hope, enabling earlier detection of cancer when treatment is most effective, significantly enhancing the prospects of successful outcomes and transforming the landscape of cancer care in the country.
Early detection of these cancers can increase 5-year survival rates to as high as 99%. The following are some examples of the significant increases in survival rates that can result from early detection.
Early vs. Late Cancer Diagnosis 5-Year Survival Rates
Breast cancer: Early stage (98 percent) vs. late stage (28 percent)
Prostate cancer: Early stage (99 percent) vs. late stage (30 percent)
Colorectal cancer: Early stage (91 percent) vs. late stage (14 percent)
How Does LucenceINSIGHT™ Testing Work?
LucenceINSIGHT™ works by conducting a single blood test to screen for signatures of multiple cancers, including breast, ovarian, cervical, pancreatic, liver, colorectal, stomach, prostate, and bladder cancers, (when applicable). After collecting your sample, The Health Today team ships to a lab for processing. Results are provided in 7-10 days for LucenceINSIGHT™, and 14-21 days for LucenceINSIGHT™ PLUS.
Contact Us
Contact Us for Private Blood Testing!